You have asked the key question: who has been buying these huge blocks of GNTA? If it is Rosenwald, that shows his confidence in where things are going in the clinical trials. If it is a market maker, then expect them to run the price up so they can re-sell all those shares they just bought for a tidy profit. Either way, I would say that GNTA is looking good at the $6 level. The downside is probably $5 1/2, but it could easily run back to $7 1/2 on the upside. That's why I just bought.